Associated Papers
RNF213 and cardiovascular disease: A review of histopathological, genetic perspectives, and potential molecular mechanisms.
Kawakami T et al.
Journal of Cardiology, 2026
Moyamoya disease: epidemiology, clinical features, pathogenesis, diagnosis and therapeutic interventions.
Cheng X et al.
Molecular Biomedicine, 2025
CXCL12/CXCR4 pathway as a novel therapeutic target for RNF213-associated pulmonary arterial hypertension.
Hiraide T et al.
Scientific Reports, 2024
MMD-associated RNF213 SNPs encode dominant-negative alleles that globally impair ubiquitylation.
Bhardwaj A et al.
Life Science Alliance, 2022
RNF213-Associated Vascular Disease: A Concept Unifying Various Vasculopathies.
Hiraide T et al.
Life (basel, Switzerland), 2022
The Genetic Basis of Moyamoya Disease.
Mertens R et al.
Translational Stroke Research, 2022
RNF213 Variant Diversity Predisposes Distinct Populations to Dissimilar Cerebrovascular Diseases.
Lin J et al.
Biomed Research International, 2018
Mutation of rnf213a by TALEN causes abnormal angiogenesis and circulation defects in zebrafish.
Wen J et al.
Brain Research, 2016
Temporal profile of magnetic resonance angiography and decreased ratio of regulatory T cells after immunological adjuvant administration to mice lacking RNF213, a susceptibility gene for moyamoya disease.
Kanoke A et al.
Brain Research, 2016
The Pathophysiology of Moyamoya Disease: An Update.
Bang OY et al.
Journal of Stroke, 2016
Temporal profile of the vascular anatomy evaluated by 9.4-tesla magnetic resonance angiography and histological analysis in mice with the R4859K mutation of RNF213, the susceptibility gene for moyamoya disease.
Kanoke A et al.
Brain Research, 2015
Select a paper to view details